Your Flagship Event Driving ADC Innovation, Insights & Connections

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Spotlighting the Clinical Performance of Izalontamab Brengitecan Bispecific ADC

Spotlighting the Clinical Performance of Izalontamab Brengitecan Bispecific ADC

4:00 pm - Wednesday 14th October 2026

Breaking down design and development of Iza-Bren, a EGFR/HER3 bispecific ADC, including advantages against traditional monospecific ADC therapies
Evaluating Iza-Bren clinical profile based on recent clinical trials
Laying out ongoing clinical development of Iza-Bren through bispecific ADC advantages and impactful clinical profile

Speakers:

Giorgia Vicentini

Giorgia Vicentini

Vice President - Global Program & Oncology Lead

Bristol Myers Squibb